Navigation Links
Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Date:2/9/2009

, PRO 2000 had undergone extensive safety testing in several clinical trials involving women and men in the United States, Europe, Africa and India.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA XR(TM), NEBIDO(R) , VANTAS(R) and SUPPRELIN(R) LA; need for additional funds and corporate partners, including for the development of our products; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR(TM); reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the R
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
2. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
3. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
4. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
5. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
6. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
7. Indevus Announces Submission of New Drug Application
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 Investor-Edge has initiated ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ), ... (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... be accessed at: http://investor-edge.com/register . On Tuesday, ... 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to ...
(Date:11/26/2014)... , Nov. 26, 2014  CARsgen, a leader in ... immunotherapy to treat a variety of cancers, today announced ... BVCF, a China -based healthcare private ... company focused on the development of new therapeutics for ... Shanghai Cancer Institute and Shanghai Renji Hospital, the company ...
(Date:11/26/2014)... -- At the American Dental Association,s Annual Meeting in ... Group was honored to be part of the 2014 ... see and test the Best of Class winners and ... the latest developments in dental technology. This year, featured ... Caries Detection Device and Kerr Demi ™  Ultra ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... Aug. 4 Tolerx, Inc. , a ... and cancer by modulating T cell activity, today announced ... Ph.D., as Chief Scientific Officer. Dr. de Fougerolles’ appointment ... research and early-stage product development programs involving novel therapies ...
... Healthcare, Inc. (Nasdaq: GRMH ) will host a conference ... , to discuss the company,s financial results for Q2, 2010. Management will review ... , , , ... be webcast on the investor relations section of Graymark,s website at http://www.graymarkhealthcare.com ...
Cached Medicine Technology:Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 2Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 3Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 4Graymark Healthcare, Inc. to Host Conference Call to Discuss Q2 Financial Results 2
(Date:11/26/2014)... 26, 2014 With a redesign of ... Steven Meier has enhanced the user experience and ... prospective patients an online destination for orthopedic and sports ... present the new and improved version of the website. ... easier than ever for current and prospective patients to ...
(Date:11/26/2014)... ISI Telemanagement Solutions, Inc., a leading ... the 2014 Lync Pioneer Award by ... a great honor to ISI, who continues to ... ISI offers an integrated collaboration reporting and recording ... voice, video, Lync IM, and conferencing. , ...
(Date:11/26/2014)... For those with a New Year’s resolution to get in ... at the University of Colorado Anschutz Health and Wellness Center ... 45- 60 minute classes have just started and are included ... memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, condition and ... fast results , By focusing on low weight loads ...
(Date:11/26/2014)... Youngsters who enter puberty early are at increased risk ... was linked with a number of factors associated with ... according to the researchers. Early puberty was also linked ... peers, and having friends who were prone to getting ... found an association between early puberty and these factors, ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 (HealthDay ... and Drug Administration will have many restaurant chains posting calorie ... movie theater popcorn and ice cream parlor fare. "Americans ... often consuming less nutritious food and underestimating the calories they ... afternoon news conference. Although listing calorie counts on ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 3
... , MONDAY, March 28 (HealthDay News) -- Teenagers ... likely to start using marijuana by the time they,re 17, ... birth cohort study that began in 1994 found that by ... and 12 percent of boys had used marijuana or other ...
... San Diego School of Medicine claim that the availability of ... that surgery should become an important part of the primary ... C. Chang, PhD, MPH, MBA, director of Outcomes Research in ... out that surgery in the United States continues to be ...
... ANN ARBOR, Mich. Most women face only a small ... treatment. Yet a new study from the University of Michigan ... speak little English expressed a great deal of worry about ... for some women, these worries can be so strong that ...
... recognizes and neutralizes or destroys toxins and foreign pathogens ... result when the system attacks the body,s own tissues ... sclerosis (MS). MS is a serious condition in which ... spinal cord are destroyed as a result of misdirected ...
... , SUNDAY, March 27 (HealthDay News) -- Baseball ... finds a new study. Researchers analyzed data from more ... and found that pitchers whose teammates were hit by a ... the temperature reached 90 degrees F than on cooler days. ...
... study published today provides a new perspective on the Great ... there were remarkable improvements in life expectancy of over five ... was actually associated with an increase in suicides but reduction ... the current recession in Europe and the U.S. The study, ...
Cached Medicine News:Health News:Surgeon availability tied to survival rate in vehicle crashes 2Health News:Some women worry too much about breast cancer returning, U-M study finds 2Health News:A possible new target for treatment of multiple sclerosis 2Health News:A possible new target for treatment of multiple sclerosis 3Health News:Great Depression did not significantly improve life expectancy in the US 2
... Single Use reloadable linear stapler with ... PI™ disposable stapler is designed for use ... healthy internal tissues. The instrument places a ... when using the 30 VASCULAR cartridges) of ...
... Single Use Loading Units With ... ILA™ 75 (Single Use Reloadable ... ,INDICATIONS The ILA™ 75 single-use ... for use in the resection, ...
... 75 single-use stapler, anastomotic type, is ... transection, and/or the anastomosis of normal, ... ILA™ 75 single-use stapler, anastomotic type, ... resection, transection, and/or the anastomosis of ...
... The PROXIMATE HCS Procedure for Prolapse and ... of titanium staples in 33mm diameter size. ... canal for transection and resection of internal ... surgical treatment of hemorrhoidal disease. The PPH01 ...
Medicine Products: